Patient Outcomes after Radiotherapy of Prostate Cancer. Impact of Absorbed Dose and Treated Volume. by Rasmusson, Elisabeth
LUND UNIVERSITY
PO Box 117
221 00 Lund
+46 46-222 00 00
Patient Outcomes after Radiotherapy of Prostate Cancer. Impact of Absorbed Dose
and Treated Volume.
Rasmusson, Elisabeth
2020
Document Version:
Publisher's PDF, also known as Version of record
Link to publication
Citation for published version (APA):
Rasmusson, E. (2020). Patient Outcomes after Radiotherapy of Prostate Cancer. Impact of Absorbed Dose and
Treated Volume. (1 ed.). Lund: Lund University, Faculty of Medicine.
General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors
and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the
legal requirements associated with these rights.
 • Users may download and print one copy of any publication from the public portal for the purpose of private study
or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain
 • You may freely distribute the URL identifying the publication in the public portal
Read more about Creative commons licenses: https://creativecommons.org/licenses/
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove
access to the work immediately and investigate your claim.
Patient Outcomes after Radiotherapy 
of Prostate Cancer
Impact of Absorbed Dose and Treated Volume
ELISABETH RASMUSSON  
DEPARTMENT OF CLINICAL SCIENCES, LUND | LUND UNIVERSITY
Department of Clinical Sciences, Lund
Division of Cancer Epidemiology and Oncology
Lund University, Faculty of Medicine 
Doctoral Dissertation Series 2020:98 
ISBN 978-91-7619-960-2
ISSN 1652-8220 9
78
91
76
19
96
02
Elisabeth Rasmusson is a radiation oncologist working at Skåne University 
Hospital, Sweden, since 2007. She also has a Master of Science degree in 
Chemical Engineering and has previously worked in the process industry. The 
overall aim of this work was to investigate the outcome of radiotherapy for 
prostate cancer in the clinical settings. A specific aim was to study associations 
between radiation dose and outcome (tumour response and/or side effects).
Patient Outcomes after Radiotherapy of Prostate Cancer 
–Impact of Absorbed Dose and Treated Volume

Patient Outcomes after  
Radiotherapy of Prostate Cancer 
Impact of Absorbed Dose and Treated Volume 
Elisabeth Rasmusson 
DOCTORAL DISSERTATION 
which by due permission of the Faculty of Medicine, Lund University, Sweden, 
will be defended in the Torsten Landberg Lecture Hall, Department of 
Oncology and Radiation Physics on September 25th at 9.00  
Faculty opponent 
Associate Professor, senior consultant Mikael Johansson 
Department of Radiation Sciences, Umeå University, Umeå 
Organization 
LUND UNIVERSITY 
Document name 
Doctoral dissertation 
Date of issue 
2020-09-25 
Author(s) Elisabeth Rasmusson Sponsoring organization
Title and subtitle 
Patient Outcomes after Radiotherapy of Prostate Cancer − Impact of Absorbed Dose and Treated Volume 
Abstract 
Backgound 
Prostate cancer is the most common form of cancer in men in Sweden. Radiotherapy, including external beam 
radiation therapy (EBRT) and brachytherapy (BT), is important treatment alternatives to surgery and active 
surveillance. Precise delivery of the prescribed absorbed dose to the prostate with minimal irradiation of normal 
tissue, specifically organs at risk, is crucial for optimal tumour response and limited side effects. The overall aim 
of this work was to investigate the outcome of radiotherapy for prostate cancer in the clinical settings. A 
specific aim was to study associations between radiation dose and outcome (tumour response and/or side 
effects) when applicable. 
Material and methods 
The studies were based on clinical patient data.Lymphedema was studied in 22 patients treated with EBRT 
including large pelvic volumes in combination with high-dose-rate (HDR)-BT and hormonal therapy after 
lymph-node dissection. Tumour outcome was studied retrospectlively in 195 patients treated with low-dose-
rate (LDR)-BT at Skåne University Hospital. Erectile dysfunction (ED) after EBRT was studied in 673 patients, 
treated in the HYPO-RT-PC randomised phase 3 trial comparing conventional fractionation (CF) with 
ultrahypofractionation (UHF). Long-term incidence of hip complications after EBRT was studied in 351 patients 
using outcome data from the National Prostate Cancer Datatbase, PCBaSe. 
Results: 
A low rate of lymphedema was found in the group of high-risk node-positive cancer patients, supporting the 
feasability of this extensive treatment. Excellent outcomes were found in the cohort of low-risk prostate cancer 
patients treated with LDR-BT showing a biochemical failure-free survival (BFFS) rate of 95.7% at 5 years with 
few side effects. The dose to the prostate ( D90%) was significantly associated with BFFS. The frequency of ED 
was similar in the CF and UHF treatment groups. Age was the strongest predictor of severe ED followed by 
dose to penile bulb (PB) beeing most evident for younger patients. EQD2-corrected doses of D2 % < 50 Gy and 
Dmean < 20 Gy to PB are suggested as treatement planning objectives in order to minimise ED after EBRT. No 
increased risk of hip fracture was found after radical radiotherpy but an increased risk of clinically relevant 
osteoarthritis was observed. These results indicate that osteoarthritis after EBRT is reduced by limiting the 
volume of the femoral heads receiving more than 40 Gy (EQD2).  
Conclusions: 
Toxicity was acceptable after treating pelvic nodes with EBRT. Significant associations were found between 
dose coverage and tumour-control in LDR-BT, between dose to PB and ED and dose to femoral head and 
ostearthritis, following EBRT. These findings add valuable information in the design of future radiotherapy 
regimens. 
Key words 
Prostate cancer,external beam radiotherapy, low-dose-rate and high-dose-rate brachytherapy, dose−response, 
side effects, lymphedema, erectile dysfunction, hip complications, ultrahypofractionation  
Classification system and/or index terms (if any) 
Supplementary bibliographical information Language 
English 
ISSN and key title 1652-8220 ISBN 978-91-7619-960-2 
Recipient’s notes Number of pages 76 Price 
Security classification
I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant 
to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation. 
Signature     Date 2020-08-13 
Patient Outcomes after 
Radiotherapy of Prostate Cancer 
Impact of Absorbed Dose and Treated Volume  
Elisabeth Rasmusson 
Cover photo by Kennet Ruona 
Copyright pp i-56 (Elisabeth Rasmusson) 
Paper 1 © Radiat Oncol, 2013, 8:271  
Paper 2 © Acta Oncol, 2016;55(8):1016–1021  
Paper 3 © Int J Radiat Oncol Biol Phys, 2020; 107(1):143‐151.  
Paper 4 © the Authors (unpublished manuscript)  
Lund University, Faculty of Medicine 
Doctoral Dissertation Series 2020:98 
ISBN 978-91-7619-960-2 
ISSN 1652-8220 
Printed in Sweden by Media-Tryck, Lund University 
Lund 2020  
To my friends in heaven 

ix 
Populärvetenskaplig 
sammanfattning på svenska 
Prostatacancer är den vanligaste cancern bland män i Sverige. Varje år insjuknar 
ca 10 000. Sjukdomen är starkt åldersberoende och är mycket vanlig bland äldre 
män. Latent cancer (icke kliniskt signifikant) förekommer ofta. Sjukdomen 
klassificeras som låg, mellan eller högrisk baserat på Gleason summa (tumörens 
aggressivitet), stadium och PSA.  
Val av behandling sker utifrån riskgrupp och ålder. Lågriskcancer behöver 
vanligtvis inte behandlas men bör följas med aktiv övervakning för patienter med 
mer än 15 års förväntad kvarvarande livstid. För övriga patienter finns 
behandlingsalternativ i form av operation eller strålbehandling. Ofta finns mer än 
en behandling att välja på vilket gör att biverkningsprofilen kan vara avgörande. 
Strålbehandling kan ges med strålkällan utanför (extern strålbehandling) eller 
inuti (brachyterapi, BT) kroppen. I det senare fallet appliceras strålkällan direkt i 
prostata antingen i form av radioaktiva jod- eller palladium-korn (LDR/seeds) 
eller genom att nålar sticks i prostata där en liten iridiumstrålkälla får passera 
(HDR). Genom BT kan en hög stråldos erhållas till en liten volym. Man kan 
också kombinera extern strålbehandling med BT. Så behandlar man med gott 
resultat ofta patienter med högrisk prostatacancer.  
Prostatacancer har relativt låg strålkänslighet. Därför krävs en hög stråldos för en 
botande behandling. Man försöker minimera biverkningarna genom att begränsa 
dosen till omgivande riskorgan som t.ex. tarm och urinblåsa. För detta ändamål 
används riktvärden för vilka doser som kan accepteras. Dessa baseras på 
litteraturuppgifter och erfarenhet. Stora randomiserade studier som underlag är 
sällsynt. 
Målet för denna avhandling är att studera biverkningar och tumörkontroll efter 
strålbehandling. Speciellt undersöktes samband mellan dos och behandlad volym 
i förhållande till tumörkontroll och biverkningar. Avhandlingen är baserad på fyra 
delarbeten. 
x 
Det första delarbetet omfattar 22 högriskpatienter som behandlats med 
lymfkörtelutrymning, hormonbehandling, extern strålbehandling av bäckenet 
och BT mot prostatan. Målet var att studera biverkningar efter behandlingen med 
speciellt fokus på lymfödem i form av bensvullnad. Patienterna undersöktes av 
läkare och sjukgymnast och intervjuades angående sina besvär efter en 
uppföljningstid på i medeltal 2,2 år. Vi fann att lymfödem var ovanligt och att 
majoriteten hade mycket milda besvär (förutom gällande erektil dysfunktion, 
vilket var förväntat). Studien stödjer fortsatt användning av dessa stora 
bäckenstrålfält, som undviks på vissa kliniker. En större studie med längre 
uppföljning skulle dock vara önskvärt. 
Det andra delarbetet är en retrospektiv studie av 195 lågriskpatienter, behandlade 
med LDR-BT under 2004−2008 med en medeluppföljningstid på 6,2 år. Vi fann 
en god 5- års biokemisk recidivfrihet på 95 % samt en statistiskt signifikant 
korrelation mellan dos till prostata (rapporterad som D90%) och biokemisk 
recidivfrihet. Behandlingen kan rekommenderas till patienter med gynnsam 
prognos där aktiv uppföljning inte är lämplig. 
I det tredje delarbetet studerades erektil dysfunktion hos 673 patienter 
strålbehandlade i den skandinaviska HYPO-RT-PC studien där patienterna 
randomiserades till antingen konventionell fraktionering (CF: 78 Gy/ 39 
fraktioner) eller ultra-hypofraktionerad behandling (UHF: 42,7 Gy/7 fraktioner). 
Vi studerade två möjliga riskområden i penisroten, penisbulben och crus. Olika 
dos-volym variabler togs fram för att beskriva dosfördelningen i dessa riskorgan. 
Därefter undersöktes eventuella samband mellan dos/volym och erektil 
dysfunktion. Vi fann ingen skillnad i erektil dysfunktion mellan 
behandlingsarmarna CF och UHF. Patientens ålder var den klart viktigaste 
faktorn följt av dosen till penisbulben. Dos- responssambandet var tydligast för 
yngre patienter (<65 år). Utifrån resultaten för dessa kunde vi rekommendera 
dosbegränsningar till penisbulben i form av D2% (nära maximum dos) på 50 Gy 
och medeldos på 20 Gy, vid fraktionsdosen 2 Gy. 
Det fjärde delarbetet är en studie av 346 patienter behandlade med extern 
strålbehandling i Umeå mellan 1997 och 2002 med 16 års uppföljning. Riskorgan 
i bäckenet i form av höftkulor, korsben och blygdben ritades in på 
dosplaneringsbilderna och doser/volymer för dessa togs fram. För att ta reda på 
vilka patienter som diagnostiserats med höftkomplikationer användes PCBaSe, en 
nationell databas för klinisk epidemiologisk forskning. Jämfört med 
kontrollpatienter matchade på ålder och län, fann vi ingen ökad risk för 
höftfrakturer men en ökad risk för höftledsartros. Den kom i medeltal 7,9 år efter 
strålbehandlingen och var kliniskt signifikant vilket stöds av att den i 80 % av 
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fallen ledde till operation med höftplastik. Dos-responsanalys gav ett statistiskt 
signifikant samband mellan V40Gy (andel av höftkulorna som fick dosen 40 Gy 
eller mer) och risk för höftledsartros. Medeldosen i materialet var dock låg (35,5 
Gy) och vi erhöll vida konfidensintervall för sambandet. Baserat på vårt resultat 
och andras publicerade fynd rekommenderar vi att hålla dosen till höftkulorna 
under 40 Gy där detta är möjligt utan att för den skull riskera dostäckning av 
tumör eller för hög dos till andra mer prioriterade riskorgan såsom ändtarm. 
Sammanfattningsvis visar de genomförda studierna på olika metoder för att öka 
kunskapen för dos-respons samband i kliniken. Moderna dosplaneringsmetoder 
ger ökade möjligheter till dosbegränsningar till riskorgan. Nya 
(hypofraktionerade) behandlingar ger ökade krav på att verifiera våra riktvärden 
för doser till riskorgan. Utrymmet för fortsatt arbete inom området är därför stort. 
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Abbreviations and definitions 
ADT androgen deprivation therapy 
AS active surveillance 
BED biologically effective dose 
BFFS biochemical failure free survival 
bNED biochemical no evidence of disease 
BT brachytherapy 
CF conventional fractionation, i.e. 1.8-2.0 Gy per fraction 
CT computed tomography 
CTC common toxicity criteria 
CTCAE common toxicity criteria adverse events 
CTV clinical target volume 
3D-CRT three-dimensional conformal radiation therapy 
EBRT external-beam radiotherapy 
ED erectile dysfunction 
EORTC European Organization for Research and Treatment of Cancer 
ePLND extended pelvic lymph node dissection 
EQD2 equivalent dose in 2-Gy fractions 
GU genitourinary 
HDR high dose rate 
HR hazard ratio 
IGRT image-guided radiation therapy 
xiv 
IMRT intensity-modulated radiation therapy 
IIEF International Index of Erectile Function 
IPSS International Prostate Symptom Score 
LENT/SOMA  late effects in normal tissue/subjective objective management 
analytic 
LDR low dose rate 
LQ model linear-quadratic model 
MRI magnetic resonance imaging 
NTCP normal tissue complication probability 
NVB neurovascular bundles
OAR organ at risk 
PB penile bulb
PCSS prostate cancer symptom score 
PET positron emission tomography 
PDE5i phosphodiesterase type 5 inhibitor 
PLNRT pelvic lymph node radiotherapy 
PROMs patient-reported outcome measures 
PSA prostate specific antigen 
PTV planning target volume 
QUANTEC quantitative analyses of normal tissue effects in the clinic 
RP radical prostatectomy
RT radiation therapy
RTOG Radiation Therapy Oncology Group 
SBRT stereotactic body radiotherapy 
TD5/5 “tolerance dose”, the dose that results in 5% risk of a severe 
complication within 5 years after irradiation 
TD50/5  the dose that results in 50% risk of a severe complication within 
5 years after irradiation 
xv 
TDC tissue dielectric constant 
TRUS trans-rectal ultrasound 
UHF ultrahypofractionation, i.e.≥ 5 Gy per fraction 
VMAT volumetric modulated arc therapy 
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1 
Background  
Prostate cancer 
Epidemiology 
Prostate cancer is the most common form of cancer in men in Sweden with 
about 10 000 new cases each year. The incidence escalated during the 1990s and 
early 2000s due to both an increase in diagnostic (prostate-specific antigen (PSA)) 
testing and an aging population. Although the age-specific mortality rate has 
decreased over the past fifteen years, about 2400 men still die of prostate cancer 
in Sweden each year. Latent (clinically non-significant) prostate cancer is common 
and the disease is strongly age dependent. The main  challenge facing the health 
care system is to minimise mortality due to prostate cancer while avoiding 
overtreatment (1). 
Staging and prognosis of localised disease 
Localised prostate cancer is divided into risk groups based on tumour grade 
(Gleason score), stage and PSA value. Stage is based on the TNM-classification 
(8th Edition of the Union for International Cancer Control, UICC, TNM 
classification of malignant tumours 2017). 
The risk of death due to prostate cancer in 10-15 years after diagnosis without 
curative treatment is less than 10% in low-risk patients and 20% in intermediate-
risk patients. For high-risk patients, the risk of death in five years is 20-30% (1). 
Thus, many patients have a long life expectancy and side effects of treatments 
cannot be neglected. 
  
2 
Node-positive cancer 
The spread of disease to the pelvic lymph nodes is common in high-risk patients, 
of whom at least 20% have lymph node metastases. According to the Swedish 
National Health Care Programme for Prostate Cancer, high-risk patients and 
some intermediate risk patients should be examined with either pelvic MRI/CT 
or PET/CT (using radiolabelled choline or acetate). New imaging techniques such 
as PSMA-PET are not yet recommended in the clinical setting (1). There are no 
clear recommendations for the treatment of patients with limited lymph node 
metastases. These patients have historically been thought to harbour systemic 
disease. However, the results of retrospective studies have indicated the benefit of 
local therapies (2, 3). Lymphadenectomy in combination with radical 
prostatectomy, or radiation therapy of the pelvic lymph nodes in combination 
with androgen deprivation therapy (ADT) can be offered to selected patients, 
preferably in clinical studies (1).  
Treatment options  
The optimal treatment for individual cases depends on the risk group, the 
remaining life expectancy, comorbidity and patient preferences.  
Active surveillance  
Active surveillance (AS) has been adopted in various parts of the world for 15 
years, and is now the standard of care for low-risk and selected intermediate-risk 
patients (1, 4). Apart from testing for PSA and repeated biopsies, modern AS 
programmes include MRI examination and the measurement of biomarkers as 
well as genetic testing (4). Definitive treatment of these patients is considered 
when biopsy-proven Gleason grade 5, or more than negligible grade 4 is found. 
Other factors indicating the need for definitive treatment are increasing PSA level, 
progress according to MRI or hereditary deadly prostate cancer (as BRACA-2 
mutation). About 25-50% of the patients in AS programmes require active 
treatment within five years as a result of reclassification of the risk or increasing 
PSA levels (5-7).  
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Surgery  
Definitive curative treatment can be offered in the form of surgery, i.e. radical 
prostatectomy (RP) with or without lymph node dissection. The procedure is 
performed using open retropubic, laparoscopic transabdominal or robot-assisted 
laparoscopic transabdominal surgery. Dissection of the obturator fossa nodes 
alone is now not clinical practice. Extended pelvic lymph node dissection 
(ePLND), including the obturator fossa, external and internal iliac nodes, may be 
indicated in high-risk patients. Lymph-node dissection increases the complication 
rate and the oncological benefit is uncertain (8) but provides prognostic 
information through more accurate staging (2).  
Preservation of the neurovascular bundles (NVB) reduces the rate of post-RP 
urinary incontinence (9) and increases the rate of erectile function recovery, but 
depends on tumour location. Recovery of erectile function has been reported to 
be better after robot-assisted surgery than open surgery for low-intermediate-risk 
tumours, but not for high risk tumours (10). In a prospective study of 531 men, 
it was found that age, degree of nerve-bundle preservation, preoperative erectile 
function and preoperative hypertension influenced erectile function after RP (11). 
In this study, 70% and 43% of the patients treated with bilateral and unilateral 
NVB preservation, respectively, regained baseline erectile function with or 
without PDE5i (phosphodiesterase type 5  inhibitor), while only 4% of patients 
treated with non-NVB preservation (65% of all patients) regained erectile 
function.  
Radiotherapy  
Radiotherapy (RT) of prostate cancer can be performed as external beam 
radiotherapy (EBRT), brachytherapy (BT) or a combination of both. 
External beam radiotherapy  
ERBT can be used to treat patients with low-, intermediate- or high-risk disease; 
in the last case combined with ADT. As prostate cancer is not very sensitive to 
radiation, several dose escalation studies have been performed in order to improve 
tumour control. Several randomised dose-escalation trials have reported a lower 
risk of biochemical recurrence in the prescribed dose interval 74-80 Gy using 
conventional 2 Gy fractions than with former standard-of-care schedules with 
total doses in the range of 64-70 Gy (12-15). 
4 
Based on the high radiation-fraction sensitivity of prostate cancer several trials 
have been performed using hypofractionated RT have been performed as a means 
of increasing the therapeutic ratio. Hypofractionation is generally categorised as 
moderate hypofractionation or ultrahypofractionation (UHF) with fraction sizes 
in the range of 2.4-3.4 Gy and ≥5 Gy, respectively. The result of published studies 
indicate that moderate hypofractionation is safe and results in disease control 
comparable to that accomplished with CF and the clinical practice has thus be 
changed at many RT centres (16).  
UHF RT for prostate cancer is not yet the standard of care, although many studies 
are ongoing, and the results obtained so far seem promising (16). Five-year 
outcomes from a large randomised UHF study, the Scandinavian HYPO-RT-PC 
trial, have recently been reported (17). The UHF schedule in this trial (7 fractions 
of 6.1 Gy each) was found to be non-inferior to CF regarding failure-free survival, 
with similar late side effects in the treatment arms. Stereotactic body radiotherapy 
(SBRT) is a variant of UHF in which typically 1-5 fractions are precisely delivered 
to a target using either a conventional linear accelerator or a robotic-based 
radiosurgery system. Prostate SBRT has been shown in multiple prospective phase 
I-III trials and single institution reviews to be both safe and effective for the
treatment of intermediate-risk patients (18).
MRI is recommended for structure delineation for treatment planning due to its 
high soft-tissue contrast compared to CT. Dose planning with MRI as the only 
imaging modality has been studied but the benefit of treating patients with this 
method has yet not been fully evaluated (19). Intensity-modulated radiotherapy 
(IMRT) or volumetric modulated arc radiotherapy (VMAT) have become the 
standard RT techniques for the treatment of prostate cancer, as it allows the 
delivery of highly conformal radiation dose distributions. The prostate is not a 
fixed organ and can change position slightly inside the body depending on how 
full or empty the lower bowel (rectum) and bladder are. To obtain good dose 
coverage of the target volume with small CTV (clinical target volume) to PTV 
(planning target volume) margins, image-guided techniques based on e.g. 
implanted markers have been developed.  
There is no strong evidence of the benefit of adding EBRT of the pelvic lymph 
nodes (PLNRT) (20, 21). Studies suggest that patients with limited disease (≤4 
positive lymph nodes) benefit from this treatment (22) and that the toxicity is 
acceptable (22, 23). Results from the NRG Oncology/RTOG 0534 SPPORT 
Trial comparing EBRT of the prostate bed with and without ADT and with 
addition of PLNRT were presented at ASTRO 2018 (24), and showed significant 
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improvement in freedom from progression with addition of PLNRT in the post-
operative setting, however these findings have not yet been published.  
Brachytherapy  
BT is a form of radiotherapy in which the radiation source is positioned inside or 
next to the volume requiring treatment, in this case the prostate. BT can be 
delivered at a high dose rate (HDR) or a low dose rate (LDR). Both methods 
requires that the patient be anaesthetised for insertion of the sources. Trans-rectal-
ultrasound (TRUS) is used for guidance during implantation. The main organs 
at risk (OAR) are the urethra and the rectum. BT can be used as monotherapy or 
combined with EBRT. The main advantage of BT is that the irradiation affects 
primarily a localised volume around the radiation source, with a very steep dose 
fall-off. In addition, if the treated organ moves within the body during period of 
treatment, the radiation source should retain its position in relation to the organ. 
However, LDR seeds may migrate. The volume of normal tissue irradiated is 
relatively small compared to the use of EBRT, which facilitates dose escalation 
and high doses per fraction.  
In LDR-BT radioactive seeds (iodine-125 or palladium-103) are permanently 
implanted via temporarily inserted catheters. Images are acquired, with the catheters 
in place using TRUS, and then transferred to a treatment planning system where 
the prostate and OAR are delineated. The position of the seeds along the catheters 
is optimised, to achieve the stipulated objectives for dose coverage and the dose to 
the OAR. Typically 50-90 seeds are implanted. A post-implant CT scan is 
commonly used for verification and optional implantation of extra seeds. The 
development of the method started in the mid-1980s when TRUS was developed, 
as this is essential in determining the optimal positions of the seeds. There are 
mature data supporting the use of LDR as monotherapy for low-risk patients and 
selected intermediate-risk patients, with disease control rates over 90% (25). 
In HDR-BT the absorbed dose is delivered by an iridium-192 source via 
temporarily inserted catheters. Images are acquired with the catheters in place 
using TRUS (sometimes supplemented by MRI or CT-scan). The images are then 
transferred to a treatment planning system where the prostate and OARs are 
delineated, as described above. Anatomy-based inverse planning and manual 
optimisation are used to define the iridum-192 source dwell time at each position 
along the catheters, in order to achieve the stipulated objectives for dose coverage 
and dose to OARs. There is growing evidence supporting the use of monotherapy 
HDR-BT in patients with low-or intermediate-risk disease but this is not a 
standard-of-care (25). EBRT (typically 25 x 2.00 Gy) combined with HDR-BT 
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boost (typically 2 x 10 Gy), is an aggressive local treatment used for high-risk 
patients, showing good results (26, 27). Pelvic lymph nodes have been included 
in the EBRT target volume in some non-randomised studies with acceptable 
radiation toxicity (28, 29). 
Androgen deprivation therapy  
ADT is widely used in the palliative setting for hormone-sensitive prostate cancer. 
In the curative setting neoadjuvant and adjuvant ADT are combined with RT for 
high-risk patients as this appears to have a synergistic effect with RT by preventing 
DNA repair (30-32). Adjuvant ADT is sometimes given after surgery to patients 
with a high risk of recurrence(1). 
Disease control after definitive treatment 
Both surgery and RT are alternatives for definitive treatment. A few observational 
studies have indicated improved survival following surgery (RP) compared to RT. 
However, this could be due to selection bias, as the patients treated with RT are 
older and have more comorbidity (33). The outcome after 10 years has been 
reported in a randomised study, the ProtecT-trial, including 1643 patients 
comparing AS, surgery and RT (with neo-adjuvant and concomitant ADT) for 
low- and intermediate-risk patients (6). It was found that the prostate-cancer-
specific mortality was low (approximately 1%) irrespective of the treatment, with 
no statistically significant differences. AS was associated with a higher incidence 
of disease progression and metastases, and 55% of the AS patients received local 
treatment within 10 years (19% in 9 months). 
In high-risk patients, treatment with EBRT+BT combined with ADT has been 
reported to be associated with significantly lower prostate-cancer-specific 
mortality and longer time to distant metastases compared to EBRT with ADT or 
RP (26, 34, 35). However, there is a risk of bias as patients receiving BT are 
selected based on suitability for anaesthesia, having a maximum prostate volume 
of 50 cm3 and not having lower urinary tract symptoms i.e. healthier patients. 
The BT boost can be delivered with either LDR or HDR (36). The ASCENDE-
RT trial, a randomised trial comparing 46 Gy EBRT to the pelvis followed by 
either EBRT to the prostate up to 78 Gy or LDR BT-boost (minimal peripheral 
dose of 115 Gy) for intermediate- and high-risk prostate cancer revealed the same 
advantage of BT boost. Men randomised to the LDR-BT boost were twice as 
likely to be free of biochemical failure at a median follow-up of 6.5 years (37). 
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Comparison of side effects after definitive treatment 
Observational and randomised data regarding urinary, erectile, and bowel 
function indicate few long-term (>5 years) differences between surgery and RT, 
although short-term urinary continence and erectile function appeared to be 
worse following surgery, and short-term urinary bother and bowel function 
seemed to be worse following RT (1, 38). Other complications such as 
hospitalisation, the need for urological, recto-anal, and other major surgical 
procedures, and secondary cancers have been shown to be more common among 
men treated with RT (38). This could be due to bias as RT patients are older and 
have more comorbidity. ADT, frequently co-administered with RT, contributes 
to additional morbidity for example, cardiovascular disease, osteoporosis, sexual 
dysfunction and depression (38).  
Side-effects 10 years after treatment were studied in the ProtecT-trial (39). 
Urinary incontinence was found to be significantly increased following surgery, 
compared to AS and RT. Surgery (RP) and RT both reduced erectile function in 
the first year after treatment with a larger decline for RP. At 6 years 29% of RT 
patients and 15% of RP patients reported erections sufficient for intercourse, 
compared to baseline values of 63% and 66%, respectively. The erectile function 
for the AM patients declined gradually over time to 35% at 6 years, compared to 
baseline value of 68%. The differences were statistically significant. These results 
reflect the influence of both treatment and aging. 
A partly randomised, prospective cohort study, CEASAR (40), confirmed a 
greater decline in sexual function scores after 3 years’ follow-up in patients 
receiving RP than in EBRT patients for the 25% of men with excellent baseline 
scores. The outcome for the patients with somewhat lower baseline functions was 
poor, regardless of whether they underwent RP or EBRT. Urinary incontinence 
scores were worse following RP than EBRT or AS. Urinary irrigation scores 
improved in RP patients. No clinically significant differences in bowel or 
hormone function were noted beyond 12 months 
LDR-BT is reported to be associated with increased genitourinary toxicity 
compared to EBRT, HDR-BT and RP (25, 27, 41). The results of non-
randomised studies (and one randomised study on RP compared to BT) suggest 
that LDR-BT might be associated with a lower risk of ED than surgery or EBRT 
(41-44). The ASCENDE-RT trial (45) reported that LDR-BT boost led to a 
higher incidence of both acute and late GU morbidity than EBRT boost, the latter 
being manifested as urethral stricture in about 50% of the cases. No difference in 
the frequency of ED were reported. 
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Concerning secondary cancer, a meta-analysis of studies revealed a 65-80% 
increased risk of cancers of the bladder, colon and rectum after RT, compared 
with the risk in those not exposed to RT but the reported absolute rates were low 
(1-4%) (46). Long-term follow-up (12 y) in a study comparing EBRT +ADT to 
ADT, SPCG 07, (47) revealed a 20% increase in all secondary cancers, and a 
250% increase in bladder cancer. However, this was outweighed by the improved 
overall survival of RT patients.  
Radiobiology 
Tumour growth and radiation sensitivity 
The growth rate of a tumour is determined by the rates of cell production and cell 
loss. Cell production is determined by the proportion of actively dividing cells 
(the growth fraction) and the cell-cycle time. The growth fraction can be 
measured in tumour biopsies using, for example the Ki67 labelling index (the ratio 
of cells staining positively for the cell-cycle protein Ki67) (48).  
In prostate cancer the Ki67-index is usually low, with mean values of less than 
10%, which can be compared with 30% for head and neck cancer and 37% in 
non-small-cell lung cancer (48, 49). The use of the Ki67 index has not been 
established in clinical practice for prostate cancer, but has been suggested to be a 
predictive marker of biochemical/clinical recurrence after RT independently of 
established prognostic factors, including the Gleason score (50). 
The cell-cycle time is more difficult to measure, but has been determined to be 
slightly shorter in adenocarcinoma (the most common cancer in the prostate) than 
in squamous-cell carcinoma or melanoma. The cell-loss factor in malignant 
tumours is quite high, often greater than 80%, and the value for prostate cancer 
has been reported to be as high as 97%. (48).  
Radiation sensitivity is the relative susceptibility of cells or tissues to the damage 
caused by radiation. In general, cell radiosensitivity is directly proportional to the 
rate of cell division and inversely proportional to the degree of cell differentiation. 
Prostate cancer is usually well-differentiated and slow-growing, and is considered 
to have a fairly low radiosensitivity, consequently requiring a high absorbed dose 
for tumour control (48). 
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Fractionation 
Cell survival and the linear-quadratic model 
A cell-survival curve describes the relationship between the fraction of surviving 
cells (S) and the radiation dose (D) (Figure 1). When plotted on a log-linear scale 
the curve is typically non-linear and the initial part is often termed the “shoulder”. 
It can be mathematically fitted by a second-order (linear-quadratic) equation such 
as the linear-quadratic or LQ-model, i.e. 
− ln(𝑆) = 𝛼 ∙ 𝐷 + 𝛽 ∙ 𝐷ଶ  
where   and   are constants. The degree of curvature (shoulder) of the cell-survival 
curve can be conveniently described by the quotient of the constants, α/β (unit 
Gy). 
 
Figure 1. Schematic cell survival curves for α/β=3 Gy and 10 Gy both with surviving fraction of 0.55 at 2 Gy. 
The LQ-model is widespread in both experimental and clinical radiobiology. DNA 
double-strand breaks are believed to be the primary mechanism leading to cell death. 
The linear component (αD) is often referred to as being the result of single-track 
events which are non-repairable, while the quadratic component (βD2) may result 
from two-track events which are repairable. Cell lines with a high α/β value have 
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nearly-constant rates of cell killing with increasing dose, while cell lines with a low 
α/β value show a pronounced curvature, the rate of cell killing per unit dose being 
higher at higher doses. The dose range in which the LQ model is valid has been 
debated but according to Joiner (48) seems to work extremely well up to 5-6 
Gy/fraction. Brenner suggests that the model is reasonably valid up to about 10 
Gy/fraction, and could possibly be used up to 18 Gy/fraction (51). The basic LQ 
model does not take the overall treatment time into account. For rapidly proliferating 
cells (early responding tissues) a correction should be considered for treatment time.  
For fractionated irradiation with complete repair and negligible proliferation 
between fractions, the shape of the cell survival curve is repeated for each fraction. 
Hence, the cell survival after n fractions, each with a dose, d, and total dose 𝐷 =
𝑛 ∙ 𝑑 can be written: 
− ln(𝑆) = 𝑛(𝛼 ∙ 𝑑 + 𝛽 ∙ 𝑑ଶ) = 𝐷 ∙ (𝛼 + 𝛽 ∙ 𝑑) 
The biologically effective dose for tumour/tissue effects. 
The LQ model can also be applied to the effects (E) of radiation on tumour or 
tissues. Assuming that E is proportional to the logarithm of the surviving fraction 
of cells responsible for the tissue effect, i.e. 𝐸 = −ln (𝑆), the LQ-model for 
fractionated irradiation can be written: 
𝐸 = 𝐷 ∙ (𝛼 + 𝛽 ∙ 𝑑) 
Fowler (52) defined the concept of the biologically effective dose (BED) as 𝐸/𝛼 
for reporting the fractionation-corrected dose: 
𝐵𝐸𝐷 = 𝐸𝛼 = 𝐷 ∙ ൭1 +
𝑑
𝛼 𝛽ൗ
൱ 
Another very useful concept for reporting the fractionation-corrected dose is the 
concept of the equivalent dose at 2 Gy per fraction (EQD2). If an arbitrary 
fractionation schedule of n fractions each with a dose d to a total dose D has the 
same BED as a 2-Gy schedule with total dose EQD2, i.e. they are iso-effective for 
a specific endpoint, then 
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𝐸𝑄𝐷2 = 𝐷
𝑑 + 𝛼 𝛽ൗ
2 + 𝛼 𝛽ൗ
 
where α/β is the fractionation sensitivity for the tissue effect studied. 
As mentioned above, the LQ model assumes that the interval between fractions is 
sufficiently long to allow full recovery between fractions (usually at least 6 hours). 
If this assumption is not valid, a correction must be made for incomplete repair. 
The influence of incomplete repair is determined by the repair half-time (T½) of 
the cells in the irradiated tissue (48). 
Fractionation sensitivity 
The relationship between the total dose and the dose per fraction for the tumour 
and the surrounding normal tissues, i.e. the fractionation sensitivity (α/β) is 
important for the optimisation of RT schedules. With knowledge of α/β the LQ 
model (or BED or EQD2 equations) can be used to calculate such relationships. 
The steepness and curvature of the curves are determined by α and β. For early-
responding normal tissue the quotient α/β is high (typically 7-20 Gy), while a low 
value of α/β (0.5-6 Gy) is characteristic of late-responding normal tissue. Many 
tumours, such as squamous cell carcinomas of the head and neck and lung, have 
a fractionation response similar to that of early responding tissues i.e. a high α/β 
ratio. These tumours are suitable for hyperfractionation. 
There is now strong evidence that prostate cancer has a low α/β value, as low as 
1-2 Gy (53-55), i.e. even lower than the typical α/β of 3 Gy for late responding 
tissues. These results confirm the original findings of Brenner and Hall (56). 
There are also indications that there are no significant differences in α/β between 
different risk groups of prostate cancer (57). These results support the use of 
hypofractionation for prostate cancer to increase the therapeutic ratio for these 
tumours. 
The dose-rate effect 
Continuous low-dose-rate irradiation is equivalent to multiple infinitely small 
fractions, given without any radiation-free intervals and cell damage and repair 
takes place simultaneously. Most human tissues are less affected by irradiation as 
the dose rate is reduced probably as a result of maximum tissue recovery/repair. 
The repair half time of prostate cancer has been suggested to be 0.5-2.0 h (58, 
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59). As the dose rate is reduced the β-term is reduced (due to repair) and the cell 
survival curve become straighter.  
In some slow-growing cell lines, however, an inverse dose-rate effect has been 
described, with an increase in steepness of the survival curve when the dose rate is 
very low. A possible explanation of this could be that the low dose rate allows the 
cells to progress through the cell cycle and accumulate in G2 (the gap between 
DNA synthesis and mitosis, when the cell continues to grow and produce new 
proteins), a more radiosensitive phase (60). The value of this effect in clinical 
practice is unclear. 
The pathogenesis of side effects after RT 
Radiation treatment may lead to loss of function of normal tissue due to damage 
to the parenchymal cells in the organ and/or damage to the stroma and 
vasculature. The radiation-induced effect depends on the radiation quality, dose, 
dose rate and radiosensitivity of the affected tissue. Healing can be achieved by 
regeneration, replacement with the same cell type or repair with replacement by 
other cell types e.g. fibrosis. The response is divided in early and late effects by 
definition at 90 days after treatment (48, 60). 
Early side effects are observed during and shortly after a course of RT. They are 
seen in tissues with high proliferative activity, such as the skin and mucosa. The 
symptoms are due to loss of proliferative capacity accompanied by inflammatory 
changes. Healing is usually complete, but sometimes leads to consequential late 
side effects. Examples of early side effects after RT of prostate cancer are cystitis 
and proctitis, caused by injury to the endothelial cells (48, 60). 
Late side effects become clinically apparent in the affected organ after months or 
years. They are irreversible and sometimes progressive. The pathogenesis is 
complex involving cell death, differentiation of fibroblasts and loss of capillaries 
as well as the immune system. The clinical consequences depend on the 
architecture of the organ and the volume irradiated. The latent time for late 
radiation effects is inversely dependent on dose, i.e. the higher the dose the shorter 
the time to clinical manifestation of the effect. Examples of late side effects after 
RT of prostate cancer are ED, chronic proctitis, urethral stricture and hip 
osteoarthritis. Vascular radiation effects such as occlusion of capillaries and 
sclerosis of arterioles, probably interact with other mechanisms such as fibrosis for 
several of the end points (48, 60). 
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Dose−response relationships 
Dose−response curves and the therapeutic ratio 
A dose−response relationship is present when the risk of a specific biological effect 
increases (in frequency, severity or both) significantly with increasing dose. The 
relation between radiation dose and the frequency of a specific end point is often 
presented graphically as a sigmoid-shaped dose−response curve. The endpoint 
may be cancer control (tumour control probability, TCP) or side effects (normal 
tissue complication probability, NTCP). The aim of RT is to separate the TCP 
and NTCP curves as much as possible, i.e. to maximise the so called therapeutic 
window or therapeutic ratio. Optimisation of the dose distribution on the target 
and OAR, as well as the fractionation schedule, are examples of how the 
therapeutic ratio can be increased. Another way of improving the therapeutic 
window may be via radiosensitisers and/or radioprotectors (48). The NTCP for a 
specific endpoint does not only depend on the dose and fractionation schedule 
but also on the fractional volume of the OAR receiving a specific dose. Several 
mathematical models have been developed describing these relationships, the 
most well-known being the so- called Lyman-Kutcher-Burman model (61) 
originally applied to the clinical tolerance data published by Emami et al.(62). 
 
Figure 2. Schematic dose−response curves 
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TCP for prostate cancer 
The conventionally fractionated EBRT dose-escalation trials performed during 
the 1990s showed a significant improvement in bNED (biochemical no evidence 
of disease) with increasing dose to the prostate (63-65). As discussed above there 
is strong evidence of a low α/β for prostate cancer. In a recent meta-analysis of 
randomised trials Vogelius and Bentzen investigated the dose response and 
fractionation sensitivity of prostate cancer (55). From the dose escalation trials 
included in their study, a statistically significant dose-response gradient was found 
for bNED but not for overall survival. Heterogeneity in the data indicated that 
EQD2 >80 Gy might not improve bNED. 
Retrospective LDR-BT studies have demonstrated an association between the dose 
variable D90% (the dose received by 90% of the prostate) and bNED supporting the 
objective of target dose coverage of BED in the range of 180-200 Gy (66-68). 
NTCP, toxicity endpoints  
A detailed understanding of the causes and anatomical origins of an RT- induced 
complication is important. Several scoring systems for toxicity have been established, 
such as RTOG/EORTC (69), CTCAE (70), and LENT/SOMA (71). These can 
sometimes be combined with underlying discrete symptom-specific data. The 
QUANTEC group recommended that grading schemes based on symptoms of 
logical clinical syndromes, rather than organ-specific collections of symptoms. (72) 
A clinical grading system may not be ideal for dose−response analysis for several 
reasons, for example as that various symptoms from a single organ often are 
grouped. An example both reduced capacity of the bladder and bleeding due to 
local ulceration can be considered bladder injury, but they may have different 
dose/volume−response relationships. Another problem is that symptoms do not 
always originate from one specific organ, for example pelvic pain (72). 
Patient-reported outcome measures (PROMs) are common in clinical studies, and 
standardised grading systems such as PRO-CTCAE or other validated 
instruments are recommended. 
OAR dose-volume constraints/objectives 
Dose-volume constraints/objectives for OAR are necessary tools in daily 
treatment planning in order to minimise the risk of side effects. However, large 
prospective studies on the doses to OAR and their correlation with toxicity are 
rare. 
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Many dose-volume constraints used in the clinic today are primarily based on 
reviews of the literature such as the QUANTEC reports published in 2010 (73, 
74) which are based on pooled data from studies with different numbers of 
patients, patient selection criteria and endpoints. Of special interest for RT of 
prostate cancer are three of the QUANTEC reports on dose-volume objectives 
for gastrointestinal (GI), genitourinary (GU) toxicities and ED (75-77). However, 
dose-volume data from the 1991 compilation by Emami et al (62) are still used, 
especially for organs/side effects not covered by the QUANTEC report. Updated 
GU dose−response relationships following prostate cancer RT were published by 
Thor et al. in 2016 (78). A systematic post-QUANTEC review of tolerance doses 
for late toxicity after prostate cancer RT were published by Olsson et al. in 2018 
(79). Updated dose-volume tolerances especially for GI symptoms (scare for GU 
and ED), based on 33 studies, are presented in this review.  
More detailed information on the side effects studied specifically in the work 
presented in this thesis is given below. 
Erectile dysfunction 
Suggested mechanisms for ED include neural injury, vascular alterations and 
corporal smooth muscle changes. Haemodynamic measurements show significant 
changes in arteries and veins after RT such as venous leakage most commonly 
from the crus of penis (80). 
Studies on erectile function after RT in relation to the dose to critical erectile 
structures are mainly focused on the penile bulb (PB) and crus as OAR but other 
OAR are probably of importance. In the QUANTEC review, Roach et al. 
concluded that, “the bulb might be a surrogate for yet to be determined 
structures” and that “it is prudent to keep the mean dose to 95% of the bulb to 
less than 50 Gy” (77). A lower threshold dose (mean dose of 20 Gy), has been 
suggested in a recent publication by the CHHiP trial group (81). Vessel-sparing 
RT (sparing the crus, PB and the internal pudendal artery) has shown promising 
results in a single-arm phase 2 trial (82). A novel OAR, the prostatic plexus, has 
been suggested, to be important for erectile function. The plexus lies within the 
prostatic fascia lateral and posterior to the prostate forming the neurovascular 
bundles and entering into the corpora cavernosa. The prostatic plexus gives rise 
to the cavernosal nerves that help control the neural input for erections. 
Irradiation of the prostatic plexus is unavoidable during RT of the prostate, but it 
has been suggested that attempts should be made to avoid hot spots in the region 
(83).  
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Use of a (hydrogel) spacer between the prostate and rectum has been reported to 
reduce the dose to the PB which is associated with improved erectile function. 
The mechanism behind PB dose reduction was unclear (84). 
Bone toxicity 
Adult bone and cartilage are believed to be relatively radiation resistant, although 
there is very little epidemiological data on the dose-response relationships. 
Radiation-induced femoral head/neck toxicity such as pain, fractures, cortical 
bone thinning and necrosis are complications that may occur after RT (85, 86). 
Early RT studies reported a threshold of 30 Gy for increased risk to produce 
irreversible damage to bone tissue and joint arthropathy (87, 88). Emami et al. 
suggested TD5/5 (the dose that results in 5% risk of a severe complication within 
5 years after irradiation) and TD50/5 values of 52 Gy and 65 Gy to the femoral 
head respectively, for the end point necrosis. A small study on anal cancer showed 
that femoral neck volume receiving more than 40 Gy (V40Gy) was predictive of 
clinically significant cortical thinning (86). 
The incidence of symptomatic pelvic insufficiency fractures after RT for prostate 
cancer has been reported to be 6.8 % after 5 years, which is lower than the 
incidence reported for gynaecological patients (89). The cumulative incidence of 
hip fracture 10 years after treatment by RT has been reported to be 8.4%, 
compared to 2.6 % for patients treated with RP, i.e. significantly higher (90). In 
contrast other studies found no increase in the incidence of hip fractures after 
EBRT (91, 92). 
Hip pain has been reported to be significantly associated with the absorbed dose 
to the femoral head in a study of long-term gynaecological cancer survivors. A 
maximal mean physical absorbed dose of 37.5 Gy to the femoral head was 
recommended (93).  
Lower extremity lymphedema 
Lower extremity lymphedema typically occurs after pelvic lymph node dissection. 
For gynaecological cancer postoperative RT and the number of lymph nodes 
dissected have been reported to be associated with lymphedema (94), but this has 
not been studied extensively for prostate cancer. In RTOG (Radiation Therapy 
Oncology Group) studies with extended-field irradiation for the treatment of 
prostate cancer, genital and/or leg oedema was noted in about 5% of the patients 
and the oedema persisted in the majority of the patients (95). The lymphedema 
developed only in patients with lymphadenectomy prior to RT and appeared 
during the first treatment year. In a more recent study, the severity and frequency 
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of lymphedema were studied in 43 patients (96). All these patients underwent 
choline-PET/CT-imaging before lymphadenectomy followed by adjuvant RT of 
50Gy to pelvic nodes. Only mild cases of lymphedema were diagnosed during RT 
and no chronic lymphedema was observed.  
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Aims 
The aim of the first study (Paper I) was to investigate late toxicity, focusing on 
lymphedema, in patients with node-positive prostate cancer treated at our hospital 
with ePLND followed by EBRT of the prostate, seminal vesicles and pelvic lymph 
nodes and HDR-BT boost to the prostate. 
The second study (Paper II) was carried out to evaluate the outcome of LDR-BT 
of the prostate regarding tumour control and side effects for this treatment at our 
department, focusing on the relationship between absorbed dose and biochemical 
failure-free survival (BFFS). 
In the third study, the relationship between the absorbed dose to penile-base 
structures and erectile dysfunction (ED) was investigated in patients treated in the 
HYPO-RT-PC phase III trial comparing conventionally fractionated (CF) and 
ultrahypofractionated (UHF) radiotherapy, for the treatment of intermediate- to-
high-risk prostate cancer. Specifically, it was investigated whether any dose-
volume objectives could be recommended to reduce the risk of ED (Paper III). 
Finally, the long-term incidence of hip complications, measured as fractures, 
replacements, infections, and osteoarthritis, after EBRT, was compared with those 
in age-matched controls from the general population. Possible dose−response 
associations were also investigated (Paper IV) 
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Materials & Methods 
HDR and pelvic EBRT − Clinical examination and 
qualitative interview of patients  
A total of 26 patients with high-risk node-positive prostate cancer, treated with 
HDR-BT and large pelvic field irradiation with EBRT following ePLND and 
ADT, were invited to participate in the study. These were all the patients treated 
with this combination of therapies at Skåne University Hospital before 
2011.Twenty-two (85%) patients agreed to participate (Paper I).  
The clinical examination and the qualitative interview were performed by an 
oncologist. The patients were asked to fill in a standard quality of life 
questionnaire, the Prostate Cancer Symptom Scale (PCSS), before the visit. The 
specific symptoms were discussed with the patients. All symptoms were classified 
according to the Common Toxicity Criteria (CTC) scale 4.0 when applicable. 
The presence of lower extremity lymphedema was examined by a physiotherapist, 
specialised in lymphedema following a protocol including measurements of limb 
volume and local tissue water, palpation and questions on symptoms related to 
lymphedema. A geometric volume method was used to determine limb volume. 
Local tissue water was evaluated with a device that transmits an ultra-high 
frequency electromagnetic wave of 300 MHz into an open-ended coaxial probe 
in contact with the skin. Based on these measurements, the tissue dielectric 
constant (TDC) was calculated, directly proportional to the tissue water content. 
The number of patients in this study was small, which provided the opportunity 
to carry out qualitative research, which is very time consuming. The results from 
such a study are primarily hypothesis-generating, and must be confirmed in larger 
studies. A group of patients that had undergone extensive treatment was studied 
so that the results could be used to create a questionnaire for a larger group of 
patients. The CTC rating was used in order to be able to compare the results with 
those from other studies. The disadvantage of using CTC to classify limb edema 
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is that the difference in limb volume is a criterion, which could also be affected 
by cardiovascular comorbidity and overweight. Using the physician’s (or 
physiotherapist’s) assessment would have been less objective but may have led to 
more accurate selection of the true positive cases. An electrical device was used to 
measure the tissue water in an attempt to objectify the oedema. Another method 
of classifying edema is to use data from PROMs to reflect how the patient 
perceives his ailments.  
Retrospective follow-up and dose−response analysis of 
patients treated with LDR at Skåne University Hospital  
The patients in this study were men with low-to intermediate-risk disease treated 
before 2008 with LDR-BT without hormonal treatment, in the Southern 
healthcare region: in total 195 patients (Paper II).  
The prescribed dose to the prostate was 145 Gy. The patients were followed 
systematically with respect to side effects for at least one year. PSA levels were 
obtained from medical records starting three months after the date of implant and 
for at least five years. Biochemical failure was defined according to the Phoenix 
definition, i.e. PSA at nadir + 2 ng/ml. The primary endpoint was time to 
biochemical failure. The outcome was analysed in relation to clinical variables at 
baseline and to RT data.  
Statistical analysis was performed using the Kaplan−Meier method to estimate 
biochemical failure-free survival (BFFS), and Cox regression for univariable and 
multivariable analyses to identify and assess predictive clinical and treatment-
related factors of biochemical failure. Multivariable analysis was carried out with 
only two covariates, bearing in mind the limited number of events. The 
combination of D90% and PSA was chosen based on presumed causality and the 
results from univariable analyses. 
The advantage of studying results from patients treated at our own hospital is that 
we have easy access to patient records and treatment planning information for the 
follow-up. A disadvantage is that the results from may not be generalised to other 
clinics with different treatment routines. A retrospective follow-up is valuable for 
one’s own clinic, to confirm that the results of treatment are as expected, but also 
for the wider community when there is a shortage of randomised studies. The side 
effects in this study were not classified according to a standard scoring system 
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which is a disadvantage. A control group would have been desirable and attempts 
were made to find a matched population treated with EBRT. Unfortunately, the 
follow-up procedures were not comparable.  
ED after EBRT – Dose−response analysis of patients 
from a randomised multicentre UHF study  
Patients included in the HYPO-RT-PC trial randomised to CF (39x2.0 Gy, over 
8 weeks) or UHF (7x6.1Gy, over 2.5 weeks) with no ADT were studied (Paper 
III). Only men with a sufficient erectile function for intercourse at baseline and 
complete RT data were included, thus 673 out of the 1180 patients in the per-
protocol population.  
RT was administered with three-dimensional conformal radiation therapy (3D-
CRT) (80%) or VMAT (20%) using image guidance based initially on the 
BeamCath® technique (10%) and then implanted fiducial markers (90%). For the 
UHF patients treated with the BeamCath® technique all fractions were given with 
BeamCath® using small (4-6 mm) CTV-PTV margins. For the CF patients only 
four fractions were given with this technique while the remaining 35 fractions 
were delivered with wider margins and no IGRT (image-guided radiation 
therapy). For the patients treated with fiducial markers, an isotropic CTV-PTV 
margin of 7 mm was used in both treatment arms. 
Patients were followed up at end of RT, at three, six, nine and 12 months after 
the start of RT and then every six months. At these visits erectile function was 
assessed as: “sufficient for intercourse”, “not sufficient for intercourse” (moderate 
ED) or “severe erectile dysfunction” (severe ED).The PB and crus were 
retrospectively delineated on the treatment planning CT scans. 
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Figure 3. CT image at the cranial part of the PB with segmented penile bulb and crus. (From Paper III, reprinted 
with permission from Elsevier.) 
Dose-volume descriptors were derived from EQD2-converted dose matrices 
(α/β=3 Gy). Statistical analyses were carried out using uni- and multivariable Cox 
proportional hazard regression and logistic regression in order to find predictors 
for ED. The time-to-event analysis was also performed using hormonal treatment 
and death as competing events. 
The advantages of using patients from a large multicentre study is that the patients 
are defined according to the specific inclusion criteria, follow-up is systematic and 
site-specific deviations are accounted for. The results should therefore be more 
easily transferrable to the wider community. The patients were randomised which 
is a considerable advantage when comparing the two treatment arms. The two 
vastly different fractionation schedules could be a drawback, and it was necessary 
to rely on the validity of the LQ-model for transformation of the physical dose 
distributions to EQD2 doses based on an adopted value of α/β. On the other 
hand, clinical data from UHF treatments are of great interest in the RT 
community as there is a demand for results using these new fractionation 
schedules 
ED is a very difficult endpoint to classify and there is no objective method of 
measuring it. We had access to the physician’s assessment and PROMs from a 
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quality of life questionnaire (PCSS). PROMs were not included in the analysis 
for several reasons. The main reason was that time-to-event analyses were 
primarily performed in order to gain an understanding of the development of ED 
after RT. For these analyses two consecutive follow-ups or more were required, 
without later recovery, for defining an event. The PROMs were performed on 
fewer occasions with an increasing number of dropouts at each follow-up 
occasion. Furthermore, PROMs data are ordinal, and were therefore not directly 
suitable for this approach. There was also a discrepancy between the baseline ED 
reported by the physician and in the PROMs in about 10% of the included 
patients. The physician’s assessment of ED is based on a verbal statement by the 
patient and may be influenced by both the patient and investigator. The use of a 
more internationally accepted scoring system in the HYPO-RT-PC trial for ED 
reported by the physician, such as CTCAE, may have been better. In some studies 
on ED, the International Index of Erectile Function (IIEF), has been used, which 
has the advantages of being validated and well known, but includes other aspects 
of sexual function as desire and satisfaction. This might be valuable when studying 
sexual dysfunction but may obscure the results when analysing dose-response for 
the endpoint ED.  
Hip complications after EBRT − Dose−response 
analysis in patients with long follow-up using national 
registers  
This study was carried out on 349 patients with prostate cancer treated to curative 
dose (≥64 Gy) with EBRT during 1997-2002 in Umeå (Paper IV). All patients 
were treated with 3D-CRT. The femoral heads, pubic arch and sacrum were 
delineated as OAR. Dose-volume descriptors were derived for these OARs.  
ICD codes, were used to collect information on skeletal events for the patients, 
and 1661 matched controls through the Prostate Cancer data Base Sweden 
(PCBaSe), a national database for clinical epidemiological research  
The statistical methods used were uni- and multivariable Cox proportional hazard 
regression (HR), to analyse time to events. In addition to cause-specific HRs, 
subdistribution HRs were calculated with death and bone metastases as 
competing events. 
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The advantage of using this group of patients were that 3D dose distributions 
were available and the follow-up time was long. Registers are convenient for long-
term follow-up, but suffer from the drawback that the data are not monitored. As 
ICD codes are used for financial allocation, this information is probably of good 
quality but other variables found in registers may be subject to greater uncertainty. 
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Results and Discussion 
Low rate of lymphedema after extended pelvic 
lymphadenectomy followed by pelvic irradiation of 
node-positive prostate cancer  
The median follow-up time was 2.2 years (range 1.2-4.1). Half of the patients 
were receiving hormonal therapy at the time of examination. Their disease was 
under good biochemical control with PSA ≤0.1 in 64% and PSA <1 in all of the 
cases. None of the patients showed any clinical signs of prostate cancer. Lymph 
node dissection included a maximum of 39 dissected nodes and more than 20 
nodes were dissected in seven patients (Paper I). 
Lymphedema and other limb symptoms 
Six patients (27%) experienced grade 1 lymphedema and two patients (9%) grade 
2 while none had grade 3 or 4 according to the CTC scale 4.0. Two patients had 
been using compression stockings before the visit, and one patient was diagnosed 
with lymphedema requiring treatment, and was provided with compression 
stockings at the time of examination. More than 50% of the patients reported on 
one or more symptoms in the legs, such as swelling and pain. No correlation was 
found between the reported RT volumes and lymphedema or between the 
number of nodes dissected and lymphedema. 
Other side-effects 
Genitourinary and gastrointestinal side effects were common but usually mild, i.e. 
CTC grades 1-2. One patient had faecal incontinence of CTC grade 3. Over 70% 
of the patients had severe ED (CTC grade 3). One patient reported pelvic pain 
(CTC grade 3). This was a patient with multiple fractures in the pubic bone. The 
same patient had also lymphedema CTC grade 2. This patient had been diagnosed 
with osteoporosis and fractures before treatment for prostate cancer and reported 
unilateral ankle swelling already after lymph node dissection. Fourteen patients 
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(64%) reported only very mild side effects (CTC grade 1) apart from ED. 
Cardiovascular disease was common (in about 60%). The majority of the patients 
were physically very active. 
Discussion 
This study of 22 patients with high-risk nodal-positive disease, treated with 
extensive surgery followed by RT and ADT, showed that most patients had only 
mild and manageable late side effects, apart from ED which is an expected side 
effect of this combination of therapies. As the level of late toxicity was acceptable, 
this local treatment is deemed appropriate for patients in good clinical condition. 
The extent of surgery and the irradiated volumes probably influence the risk of 
lymphedema. The majority of these patients had undergone extended pelvic 
lymph node dissection according to general guidelines, described in the 
background, and no correlation was found between the number of nodes dissected 
and lymphedema. Nether was any significant relationship found between 
segmented pelvic nodal volumes or treated/irradiated volumes and lymphedema. 
This was not surprising as the number of patients was small. However, it should 
be noted that in three cases the nodal target volume was delineated far more 
caudally than the RTOG recommendations and these patients were all diagnosed 
with lymphedema. 
A larger study with longer follow-up is required to allow the analysis of the 
dose−response relationship and draw more reliable conclusions. It is difficult to 
obtain reliable information on lymphedema without a clinical examination, as 
many patients report symptoms in the legs, such as swelling and pain, without 
any signs of lymphedema. A larger study would be rather time consuming but 
might be possible if patients were selected based on PROMs. 
Low-dose-rate brachytherapy with I-125 seeds has an 
excellent 5-year outcome with few side effects in patients 
with low-risk prostate cancer  
The Kaplan−Meier-estimated median follow-up time for the LDR-BT patients 
was 6.2 years. At five years, 23 patients had biochemical recurrence, according to 
the Phoenix definition, but 14 of these patients were classified as bounce*, leaving 
nine patients with true recurrence of disease (4.6%), and 191 patients free from 
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disease (91.2%); eight patients lost to follow-up (4.1%). The Kaplan−Meier 
estimated BFFS at five years was 95.7% (Paper II).  
Dose−response 
D90% was found to be a significant predictor of biochemical failure, BF: (HR=0.90 
[95%CI 0.83-0.96], p=0.002). The only other variable that contributed 
significantly in the multivariable analysis was PSA before treatment; the higher 
the PSA level, the higher the risk of relapse. ROC (receiver-operating 
characteristic) curve analysis and Cox proportional hazard analysis of the most 
significant split between the Kaplan Meyer curves for BFFS suggested an optimal 
cut-off level of 167 Gy.  
There was a tendency towards better outcome in the patients treated towards the 
end of the study period. D90% was significantly correlated to treatment year 
showing increasing doses with time.  
Side effects 
The patients’ mean self-reported International Prostate Symptom Scores (IPSS) 
and “urinary bother” (last question on the IPSS form) were elevated at three 
months, but had decreased at one year, almost reaching the baseline. The same 
effect was seen for maximal urinary flow rate, which was decreased at three months 
(Figure 4). Almost half of the patients reported urinary urgency (without 
specification) after three months. This number decreased to 20% after one year. 
Urinary incontinence was rare. No correlation was found between the absorbed 
dose measured as D90% or urethra D30% and GU side effects. 
 
Figure 4. Mean values of IPSS (0-30), urinary bother (0-6) and urinary flow (ml/min). 
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About 10% of the patients treated with LDR-BT reported gastrointestinal side 
effects after 3 months, without further specification. The frequency of this 
problem had decreased to 4 % at the one-year follow-up.  
No correlation was found between D90% and ED, but information on baseline ED 
was missing for more than 40% of the patients and ED was not graded. Of the 
83 patients without ED before treatment 61% still had no ED at the 1-year 
follow-up. Patients using PDE5i were classified as having ED. 
Discussion 
This second study involved patients undergoing LDR-BT for the treatment of 
low-risk prostate cancer. The BFFS at 5 years was 95.7% and a significant 
association was found between dose and tumour control. A high BFFS is expected 
for this group of patients. The strongest predictor of BFFS was D90% which also 
remained significant in multivariable analysis. It should be noted that during the 
treatment period in this study, including the start-up, a significant trend towards 
better results concerning BFFS was observed. This could be considered a learning 
effect, and is probably mostly dosimetric, since dose to prostate (D90%) also 
increased. However, there may be other explanations. The physicians performing 
the procedure became more experienced and the selection of patients may have 
slightly shifted.  
The biopsies from all patients except one showed a Gleason score ≤6 and 90% 
had low-risk disease when including PSA and stage. AS is usually the standard of 
care today for low-risk patients; EBRT, RP or LDR-BT being alternatives. At the 
time when these patients were treated they were all considered suitable for 
definitive treatment. Today, LDR-BT is recommended for low-risk (and selected 
intermediate-risk) patients who need or request active treatment. A practical 
advantage of LDR-BT is that the patient requires a hospital stay of only one day, 
and may then return to normal life.  
Toxicity during the first year was deemed to be acceptable, with an increase in 
GU at three months, in line with similar studies with a long follow-up. A longer 
follow-up using a validated scoring system would have been needed to explore any 
dose−response associations regarding toxicity. Anyhow, the outcomes were 
excellent and support LDR-BT as a treatment alternative to selected patients. 
*Bounce: A temporary increase in PSA of more than 0.2 ng/ml above the nadir with a subsequent
return to the pre-bounce level, or to below 0.5 ng/ml
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Erectile dysfunction and absorbed dose to penile  
base structures in a randomised trial comparing 
ultrahypofractionated and conventionally fractionated 
radiotherapy for prostate cancer  
The patients included in this study were those without ED at baseline and 
available dose plans. In total, 673 patients were included (330 and 343 in the CF 
and UHF arms, respectively), i.e. 57% of the 1180 per-protocol patients in the 
trial (Paper III). 
A strong correlation was found between the dose-volume descriptors studied 
(r>0.85) for both the PB and crus. A strong correlation was also found between 
the dose distributions in the PB and crus (r>0.8). Dose−response analyses were 
therefore restricted to the PB.  
Average value (EQD2 corrected using α/β=3) of Dmean in the PB was 24.5 in CF 
and 18.7 Gy in UHF, respectively. The corresponding values for the average value 
of D2% were 52.1 in CF and 46.0 Gy in UHF. The EQD2 doses were consistently 
lower in patients in the UHF group than in the CF group, primarily due to the 
linearly scaled dose-volume objectives/constraints but also due to the differences 
in margins in the patients treated with Beam Cath®. 
Frequency of ED 
Severe ED occurred in 181 (27%) patients during the follow up period (89 (27%) 
in CF- group and 92 (27%) in the UHF-group). Severe ED was present in 74 
(11%) (37 in each treatment arm) at 12 months and in 105 (18%) (53 in the CF-
group and 52 in UHF-group) at 24 months.  
Severe/moderate ED occurred in 340 (51%) patients during the follow up period 
(166 in CF-group (50%) and 174 in UHF-group (51%)).  
Time-to event analyses 
No significant difference was seen in the development of ED (severe or moderate) 
over time between the CF and UHF groups. For the whole study population the 
only statistically significant predictor in the Cox analyses was age, in both 
univariable and multivariable analyses. Of the dose-volume descriptors tested, 
D2%, was the strongest predictor of time to severe ED (p=0.08). Further analyses 
showed that the association between dose and severe ED was strongest for the 
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younger patients in the study cohort. A strong significant association between 
dose and severe ED was found in those aged 65 years or and younger.  
Figure 5. Cumulative incidence of severe ED for D2% to the PB less than or greater than 50 Gy in patients aged 
65 years or younger. (From Paper III, reprinted with permission from Elsevier). 
Severe ED at 12 and 24 months 
All dose-volume descriptors studied were significantly associated with severe ED 
in univariable logistic analysis at 24 months, but only D2% was significantly 
associated with severe ED at 12 months; the strongest single dose predictor at 
both follow-up times. In multivariable analysis, age together with D2% were 
significant predictors of severe ED at both 12 and 24 months.  
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Figure 6. Median dose-volume histograms for patients with and without severe erectile dysfunction at two 
years.EQD2 corrected doses using α/β=3. (From paper III, reprinted with permission from Elsevier). 
A strong significant association between dose and severe ED was found at both 
12 and 24 months for the younger patients. As in the case of the whole patient 
group, D2% was the strongest dose predictor of severe ED for those aged 65 years 
or and younger.  
The best cut-off values predicting severe ED were 50 Gy for D2% and 20 Gy for 
Dmean at both 12 and 24 months (Figure 7).  
 
Figure 7. Risk of severe erectile dysfunction versus D2% and Dmean at 2 years for patients younger and older than 65 
years. The recommended cut-off values are indicated by the arrows. 
34 
Image-guided radiotherapy 
When further analysing the data, a statistically significant difference in severe ED 
was found between the CF patients treated with BeamCath® and those treated 
with fiducials as image-guidance (p=0.006). This supports an association between 
absorbed dose and severe ED as the DVHs (dose-volume histograms) differ 
considerably when using the BeamCath® technique in the CF-patients due to 
differences in the CTV-PTV margins.  
Discussion 
In this study the risk of ED in patients treated within the HYPO-RT-PC trial, 
the first published prospective randomised phase III study comparing CF RT with 
UHF RT, was evaluated. The main focus was on the impact of radiation doses to 
the penile base. The results showed that age at RT is the strongest predictor of 
ED followed by the “near maximum” dose (D2%) to the PB. However, all the 
dose-volume parameters studied were significantly associated with severe ED at 
24 months. This implies that dose-volume parameters other than D2% could also 
be of importance when defining treatment planning dose-volume objectives for 
the PB.  
We found that the best cut-off dose to prevent severe ED was at a near-maximum 
dose of 50 Gy to the PB, based on results for younger patients (≤65 years). In 
addition a mean dose of 20 Gy is suggested as a dose volume objective for the PB. 
These values can be compared to the recommendation made by the QUANTEC 
group, i.e. to limit the mean dose to the PB below 50 Gy (to 95% of the volume). 
The QUANTEC recommendation is based on the result of only a few studies. 
The largest study included (in which the dose−response association was evaluated) 
was carried out on 158 patients (77), where the mean dose to the PB was higher 
than in the present study (Paper III). The low mean dose in the present study 
could explain why the near-maximum dose (D2%) was a better predictor of ED 
than the mean dose, and also why the dose−response relationship was quite weak. 
The highest dose, probably most important for side effects, is received by the 
upper part of the PB, and reflects the doses in the surrounding tissues including 
the crus. On the other hand Dmean might be less sensitive to delineation. The 
cranial part of the bulb will have a major impact on D2%. Recently presented dose-
ED results for 233 patients without severe ED at baseline, treated within the 
CHHiP trial showed that a mean PB dose <20 Gy increased potency preservation, 
supporting the findings of the present study. 
The frequency of ED and its development over time in the present study was 
similar in the CF and UHF groups despite the fact that EQD23−corrected doses 
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to the erectile tissue were, as expected, lower in the UHF group. A complementary 
analysis with EQD22 correction (using α/β= 2 Gy) resulted in more similar dose 
distributions to the PB in the two groups. This could indicate that the value of 
α/β for the tissues involved in the pathogenesis of radiation-induced ED is less 
than 3 Gy, indicating radiation injury to slow-reacting structures, such as nerves 
and vessels. 
This study is the largest study to date on the effects of dose on ED, and is unique 
as patients treated with UHF RT are included. It therefore provides important 
contributions to our knowledge in the field.  
Long-term risk of hip complications after radiotherapy 
for prostate cancer − A dose−response study  
Of the 349 patients included in this study, data were missing for three patients in 
the PCBaSe, leaving data from 346 patients for analysis. The median follow-up 
time was 16.0 years (Paper IV).  
The median average physical dose and the corresponding equivalent 2-
Gy/fraction dose to the femoral heads were Davg = 35.5 Gy and EQD2avg = 28.7 
Gy, respectively. The corresponding median near-maximum doses were D2% = 
43.6 Gy and EQD22% = 36.9 Gy, respectively. During follow-up, a total of 20 
fractures occurred, 12 of which were hip fractures. Hip osteoarthritis was 
diagnosed in 36 cases; 29 cases leading to replacement surgery. 
No increased risk of hip fractures was found in the irradiated cohort compared to 
the control group. Hip osteoarthritis was the only event for which a statistically 
significant difference was found between the irradiated cohort and the controls 
(cause-specific HR 1.56 (95%CI: 1.07-2.26, p=0.02)). When analysing the data 
using death and bone metastases as competing risks, the subdistribution HR was 
1.44 (95%CI: 0.99-2.09, p=0.055). The cumulative incidence of osteoarthrosis 
at 10 years was 8.1% (95%CI 5.2-11.0) and 4.9% (95%CI 3.9-6.0) in the 
irradiated cohort and in the controls, respectively.  
A statistically significant relationship was found between osteoarthritis and the 
volume of the femoral head receiving an EQD2 dose of ≥40 Gy,VEQD2 40Gy, 
(unadjusted HR=1.094, 95% CI 1.041-1.149, p<0.001) (Figure 8). The cut-off 
dose of EQD2=40 Gy is close to the maximum dose in the material, hence a large 
proportion of the patients (77%) had maximum doses lower than 40Gy (VEQD2 
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40Gy = 0). When all patients with VEQD2 40Gy = 0 were excluded, leaving 81 patients 
in the analysis, a HR of 1.10 (95%CI 1.031-1.17 p=0.003) was obtained. 
Figure 8. Risk of osteoarthritis within 10 years after radiotherapy vs, VEQD2 40Gy (solid line) with 95% confidence 
intervals (dashed lines). 
Discussion 
No increased risk of hip fracture was found in the irradiated cohort compared to 
the matched controls, after a median follow-up time of 16 years. The only 
complication that was significantly worse in the irradiated cohort compared with 
the control group was hip osteoarthritis. This finding is clinically relevant, as 80% 
of patients diagnosed with osteoarthritis required hip replacement. The median 
time to hip osteoarthritis was 7.9 years. This finding is in line with that by Zelefski 
et al. (91), who reported a low incidence of long-term hip-related toxicity after a 
median follow-up period of seven years.  
The only dose−response combination found to be statistically significant was 
between VEQD2 40Gy and hip osteoarthritis, although the confidence interval was 
wide (Figure 8). This dose−response relationship must thus be confirmed in other 
studies before it is recommended as a dose-volume objective in the clinic. To the 
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best of the author’s knowledge no dose-volume objectives have been published for 
the endpoint osteoarthritis.  
Apart from the low absorbed doses to the hip mentioned above, other limitations 
of this study are associated with the information available in the various national 
registers, as discussed above. Including the femoral neck in the delineation 
(according to the RTOG (25)) would have improved this study as this is the most 
common fracture site.  
The patients in this study were treated with CF 3D-CRT. Nowadays most 
patients with prostate cancer are treated with (hypofractionated) VMAT, which 
may lead to higher doses to the femoral heads. In addition, pelvic lymph nodes 
are sometimes included, which also affects the absorbed dose to the hip. Further 
studies should include patients treated with contemporary RT techniques to allow 
more reliable dose-volume objectives to be determined for use in the clinic. 
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Conclusions 
The main conclusions drawn from the work presented in this thesis are given 
below. 
• There was a low incidence of lymphedema in patients with high-risk node-
positive prostate cancer who have undergone pelvic lymph node dissection 
followed by HDR-BT and pelvic EBRT (Paper I). 
• Most patients treated with this combination therapy experienced low overall 
toxicity, supporting the use of large pelvic fields for patients with high-risk 
node-positive prostate cancer (Paper I). 
• The absorbed dose is a predictive factor for BFFS for low-risk patients 
without ADT, treated with LDR BT as unimodal treatment (Paper II).  
• With the treatment routines and dosimetry used, a value of D90% in the 
range of 170-180 Gy gives excellent outcomes for patients with low-risk 
prostate cancer (Paper II). 
• The frequency of severe ED is similar in groups treated with CF RT and 
UHF RT (Paper III). 
• Age at RT was the strongest predictor of severe ED, followed by dose to the 
PB, being most evident in younger patients (Paper III).  
• Values of D2 % < 50 Gy and Dmean <20 Gy to the PB are proposed as primary 
objectives in the treatment planning process (Paper III). 
• There is no increased long-term risk of hip fracture, but an increased risk of 
clinically relevant osteoarthritis after EBRT with CF RT, when mean dose 
to the femoral head is 35.5 Gy (Paper IV).  
• There is possibly a dose−response relationship between osteoarthritis and the 
volume of the femoral head receiving an EQD2 dose of 40 Gy or higher 
(Paper IV). 
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Future Perspectives 
A larger study on patients with limited lymph-node positive prostate cancer to 
compare tumour control and side effects (e.g. lymphedema and GI toxicity), with 
and without pelvic EBRT and including dose-response analysis, is desirable. A 
study of late toxicity after LDR-BT on all patients in Sweden treated with this 
technique, using PCBaSe, was intended to be included in this thesis but is not yet 
realised. The role for BT in the era of hypofractionation is challenged, so 
information on late toxicity after monotherapy BT is interesting especially if it 
can be compared to toxicity after (UHF) EBRT or RP.  
The objectives used in RT planning must be continuously evaluated as treatments 
and dose planning tools evolve. Endpoints other than ED, such as GI-toxicity 
(e.g. rectal bleeding) and GU-toxicity (e.g. urethral stricture) remain to be studied 
following UHF treatment. Much work remains to be done in defining OAR for 
the investigation of complex side-effects such as ED. The PB and crus were 
studied in the present work, but other OAR, such as the prostate plexus (including 
the nerve bundles) and internal pudendal arteries (IPAs) would be interesting 
subjects of study. Based on the result of some pilot patients we believe that these 
OAR could be delineated using standard MRI with slightly modified sequences. 
The PCBaSe is a useful source of information on late toxicity. The suggestion that 
there is a dose−response relationship between osteoarthritis and the volume of the 
femoral head receiving an EQD2 dose of 40 Gy or higher, should be confirmed 
in a larger study. A suitable clinical study could be performed on patients treated 
with contemporary technique such as IMRT/VMAT at our clinic, or at other 
Swedish radiotherapy units, with a follow-up period of ten years or more. 
Finally, a dream is that studies of dose−response analyses should be considered in 
the planning phase of new radiation studies so that robust endpoints and follow-
up for this purpose can be secured.  
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